Trials / Completed
CompletedNCT00774020
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
A 6 Months, Open-Label Phase IV Study to Confirm the Safety and Efficacy of Single Intravenous Dose of 5 mg Zoledronic Acid for the Patients of Paget's Disease of Bone (PDB) in China
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to document the efficacy and safety profiles of single intravenous dose of 5 mg zoledronic acid for the Chinese patients of Paget's Disease of Bone (PDB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic acid | 5mg, i.v. single dose |
Timeline
- Start date
- 2008-10-30
- Primary completion
- 2011-01-14
- Completion
- 2011-01-14
- First posted
- 2008-10-16
- Last updated
- 2017-02-23
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00774020. Inclusion in this directory is not an endorsement.